Athira Pharma Showcases Phase 1 Trial Insights for ATH-1105
In the field of biopharmaceuticals, ensuring the safety and efficacy of new treatments is of utmost importance. Athira Pharma, Inc. (NASDAQ: ATHA), a forward-thinking company dedicated to creating small molecules aimed at restoring neuronal health, has made significant strides as it prepares for a potential new era in the treatment of neurodegenerative diseases like amyotrophic lateral sclerosis (ALS).
At the 4th Annual ALS Drug Development Summit, Athira Pharma will present findings from its first-in-human Phase 1 clinical trial of ATH-1105, an innovative compound that has shown promise in early evaluations among healthy volunteers. This development marks a critical milestone in Athira's journey to developing effective therapies for ALS.
Positive Data from Phase 1 Clinical Trials
The Phase 1 clinical trial, which engaged a cohort of healthy volunteers, highlighted a favorable safety and tolerability profile for ATH-1105. The results indicated not only that participants tolerated the compound well, but also confirmed the drug's dose proportional pharmacokinetics and its ability to penetrate the central nervous system (CNS). These characteristics are crucial for medications aimed at treating neurological conditions, which often require effective delivery to brain tissues.
Statements from Leadership
Dr. Javier San Martin, Chief Medical Officer at Athira, expressed optimism regarding these outcomes. He stated, "We are very encouraged by these first-in-human safety and pharmacokinetic data, which strengthen ATH-1105’s potential as a treatment for ALS. We are on track for initiating a clinical trial in ALS patients and are keen to evaluate ATH-1105's effects on validated biomarkers for the disease." This enthusiasm underscores the company's commitment to advancing its lead candidate into further clinical trials.
Oral Presentations Highlighting Key Findings
The data presentation at the conference includes an oral presentation titled, "Advancing ATH-1105 for ALS Through Early Clinical and PK Data," alongside a detailed poster presentation named, "ATH-1105 Enhances Motor Neuron Survival and Reduces TDP-43 Pathology in Preclinical ALS Models." The presentations will be led by Dr. Sherif Reda and Dr. Kai-Bin Ooi, both integral to Athira's research.
Among the noteworthy highlights from the trial results are:
- ATH-1105 consistently demonstrated robust benefits in preclinical ALS models.
- Participants in the trial reported a favorable safety profile throughout both single and multiple ascending dose studies.
- Significant CNS penetration suggests effective delivery for neurological targets.
The Impact of ATH-1105 on ALS Research
ATH-1105's development is further encouraged by a growing body of research illustrating statistically significant improvements in various ALS-related parameters, including nerve and motor function and inflammation biomarkers. The compound has been discussed at prominent scientific gatherings and has garnered attention in respected journals, affirming Athira Pharma's position as a leader in addressing neurological disorders.
Understanding the Clinical Trial Process
The Phase 1 trial, registered under NCT 06432647, was a double-blind, placebo-controlled study that enrolled 80 participants to assess the safety and tolerability of ATH-1105. With its completion in 2024, this pivotal study provided insights into the pharmacokinetics of the drug, laying a foundation for further assessment in ALS patients.
Athira aims to leverage these results to expedite the transition to clinical trials involving ALS patients, bringing hope to those affected by this debilitating disease.
About Athira Pharma, Inc.
Headquartered in the Seattle, Washington area, Athira Pharma is at the forefront of developing small molecules designed to rejuvenate neuronal health and combat neurodegeneration. Through their innovative approach, they intend to not only better understand but also alter the progression of neurological diseases effectively.
For media inquiries or additional information, please reach out to Julie Rathbun at Athira Pharma via email at Julie.rathbun@athira.com or call 206-769-9219.
Frequently Asked Questions
What is ATH-1105?
ATH-1105 is a novel, orally administered small molecule drug candidate being developed by Athira Pharma to treat neurodegenerative conditions like ALS.
When will clinical trials for ALS patients start?
Athira Pharma is on track to begin trials in ALS patients in late 2025, as indicated by the outcomes of their Phase 1 trial.
What were the primary findings of the Phase 1 trial?
The Phase 1 trial demonstrated a favorable safety profile, good tolerability, and promising pharmacokinetic results, suggesting ATH-1105 can effectively target the CNS.
Who will present the data at the ALS summit?
Dr. Sherif Reda and Dr. Kai-Bin Ooi will present the findings of the Phase 1 trial at the 4th Annual ALS Drug Development Summit.
How does ATH-1105 work?
ATH-1105 modulates the neurotrophic HGF system, aimed at restoring neuronal health and potentially slowing neurodegeneration observed in ALS and similar conditions.
